What is RenovoRx, Inc. (RNXT) stock price today?

RenovoRx, Inc. (RNXT) is currently trading at $1.28, down 3.76% today.

What is RNXT P/E ratio?

RenovoRx, Inc.'s P/E ratio is -5.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is RNXT return on equity (ROE)?

RenovoRx, Inc.'s return on equity (ROE) is -145.63%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is RenovoRx, Inc.'s market cap?

RenovoRx, Inc. has a market capitalization of $57.67M.

NASDAQ · Biotechnology

RenovoRx, Inc. (RNXT) Stock

$1.28 -3.76% NASDAQ: RNXT Healthcare

Valuation

Metric	Value
Price	$1.28
Market Cap	$57.67M
P/E Ratio	-5.00
P/B Ratio	8.32
P/S Ratio	36.02
EPS (TTM)	$-0.32
52-Week High	$2.59
52-Week Low	$0.70
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-145.63%
ROA	-107.09%
ROCE	-139.74%
Gross Margin	-1300.00%
Operating Margin	-1300.00%
Net Margin	-621.71%
Debt/Equity	0.03
Current Ratio	4.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$1.0M
Operating Profit	$-6.0M	$-10.0M	$-11.0M	$-11.0M	$-13.0M
Net Profit	$-6.0M	$-10.0M	$-10.0M	$-9.0M	$-11.0M
EPS	$-0.40	$-0.54	$-0.50	$-0.37	$-0.32
Op Margin	—	—	—	-25511.6%	-1114.0%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$16.0M	$7.0M	$1.0M	$8.0M	$8.0M
Total Liabilities	$1.0M	$1.0M	$4.0M	$4.0M	$3.0M
Cash	$15.0M	$4.0M	$1.0M	$7.0M	$7.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

iAccess Alpha Virtual Best Ideas Summer Investment Conference Begins Today ACCESS Newswire · Jun 23, 2026 iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 23–24, 2026 ACCESS Newswire · Jun 18, 2026 RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer GlobeNewswire · Jun 11, 2026 RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd GlobeNewswire · Jun 4, 2026 RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-6.0M	$-9.0M	$-10.0M	$-9.0M	$-11.0M
Investing Cash Flow	$0	$-2.0M	$2.0M	$0	$0
Financing Cash Flow	$3.0M	$0	$0	$0	$-1.0M
Net Cash Flow	$13.0M	$-11.0M	$-3.0M	$6.0M	$0
Free Cash Flow	$-6.0M	$-9.0M	$-10.0M	$-9.0M	$-11.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.27
EV / EBITDA	-5.04
FCF Yield	-16.77%
Quick Ratio	5.53
Interest Coverage	0.00
Return 1Y	-34.09%
Return 3Y	-59.53%
Return 5Y	—

Ownership

Insiders Held3.42%

Institutions Held18.96%

Institutions Float Held19.64%

Institutional Holder	Shares	Report Date
AIGH Capital Management LLC	3,706,197	2026-03-31
Bleichroeder LP	1,666,098	2026-03-31
Vanguard Capital Management LLC	1,447,177	2026-03-31
Geode Capital Management, LLC	381,723	2026-03-31
Wealthspire Advisors, LLC	252,525	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANVSAnnovis Bio, Inc.	$1.21	+3.42%	-0.67	$51.48M	0.00%
BCAB	$1.74	+0.00%	-0.12	$2.88M	0.00%
CALCCalciMedica, Inc.	$1.27	-2.31%	-0.21	$4.00M	0.00%
CELUCelularity Inc.	$1.56	+6.85%	-0.51	$45.16M	0.00%
ELUTElutia, Inc.	$0.82	-0.51%	0.60	$36.39M	0.00%

About RenovoRx, Inc.

RenovoRx, Inc. is led by CEO Shaun R. Bagai, employs 10 people, headquartered in US, publicly traded since 2021.

RenovoRx, Inc. (RNXT) stock trades at $1.28 with a market capitalization of $57.67M. The stock is valued at a price-to-earnings (P/E) ratio of -5.00, price-to-book of 8.32, price-to-sales of 36.02. Over the past 52 weeks the stock has ranged between $0.70 and $2.59, and currently trades 50.6% below its 52-week high.

On profitability, RenovoRx, Inc. generates a return on equity (ROE) of -145.63%, return on capital employed of -139.74%, an operating margin of -1300.00%, a net profit margin of -621.71%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides